Advanced nucleic acid delivery solution for genetic medicine development

Thermo Fisher Scientific has launched Invitrogen™ Vivofectamine™ Delivery Solutions, a high-performance lipid nanoparticle (LNP) technology designed for the non-viral delivery of nucleic acids. This new LNP portfolio, derived from over 6,000 rationally designed ionisable lipids, offers in vivo delivery solutions with optimised efficiency, specificity, and safety profiles, accelerating progress in life science research and genetic medicine development.

One of the primary challenges in genetic medicine is safely and effectively delivering RNA or DNA to target cells without compromising integrity or causing adverse effects. The increasing adoption of LNP technology has been driven by the success of mRNA COVID-19 vaccines and growing concerns about the safety of viral delivery methods. LNP technology is gaining traction in gene replacement, cancer vaccines, gene editing therapies, and stem cell research, as well as in vivo and ex vivo immune cell therapies.

The Invitrogen Vivofectamine Delivery Solutions offer two specialised portfolios: the basic research portfolio for academic researchers and the drug development portfolio for biotechnology and biopharmaceutical companies. These portfolios help scientists reduce the time and cost of developing innovative genetic medicines.

"Building on decades of experience in lipid-based nucleic acid delivery, Vivofectamine LNPs are designed to facilitate safe and effective in vivo delivery of genetic material," said Tiffani Manolis, Vice President of Cell Biology at Thermo Fisher Scientific. "These non-viral delivery solutions are driving innovation in life sciences and paving the way for new breakthroughs in genetic medicine."

Vivofectamine LNPs are available in a variety of formats, including reagent options and value-added services. They have been extensively tested in animal models, including studies for intramuscular delivery of vaccines and systemic liver delivery. Collaborators have also demonstrated feasibility for extra-hepatic delivery to immune cells, muscles, tumours, the central nervous system (CNS), and other tissues.

Designed for research use, Vivofectamine Delivery Solutions are ideal for academic institutions and drug developers seeking reliable in vivo delivery of nucleic acid therapies.

More information online